Ascendis Pharma
ASND
ASND
184 hedge funds and large institutions have $7.61B invested in Ascendis Pharma in 2023 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 52 increasing their positions, 65 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
16% more funds holding
Funds holding: 159 → 184 (+25)
0.18% more ownership
Funds ownership: 105.48% → 105.66% (+0.18%)
20% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 65
Holders
184
Holding in Top 10
16
Calls
$26.8M
Puts
$20.7M
Top Buyers
| 1 | +$44.3M | |
| 2 | +$32.1M | |
| 3 | +$29.7M | |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$28.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$21.6M |
Top Sellers
| 1 | -$77.1M | |
| 2 | -$49.7M | |
| 3 | -$48.2M | |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$31M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$24.3M |